Elecoglipron produced clear dose-dependent reductions in body weight
Chat directly with your care team and send photos of your meals for feedback
A 2025 RAND Corporation survey of nearly 9,000 Americans found that 11.8% of US adults have used a GLP-1 medication for weight loss or diabetes, and by late 2025 consumer tracking firm Circana was reporting that nearly a quarter of all US households have at least one person actively using these drugs
Metabolism Boost: Ipamorelin increases insulin sensitivity and improves glucose utilisation, helping to improve metabolic health
49 In another phase 1 study conducted in 37 Japanese patients, the most common treatment-related side effects were nausea, vomiting, abdominal discomfort, diarrhea, and headache, mostly mild to moderate in severity